Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma

Marion Eveillard, Even Rustad, Mikhail Roshal, Yanming Zhang, Amanda Ciardiello, Neha Korde, Malin Hultcrantz, Sydney Lu, Urvi Shah, Hani Hassoun, Eric Smith, Alexander Lesokhin, Sham Mailankody, Ola Landgren, Katie Thoren

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF MS) may soon replace routine electrophoretic methods for monitoring monoclonal proteins in patients with multiple myeloma. To further evaluate the clinical utility of this assay, we compared the performance of MALDI-TOF-MS head-to-head with an established bone marrow-based measurable residual disease assay by flow cytometry (Flow-BM-MRD), using Memorial Sloan Kettering Cancer Center’s 10-color, single-tube method. Our results suggest that MALDI-TOF-MS adds value to bone marrow-based MRD testing and may be most useful for early detection of relapse in peripheral blood compared to current electrophoretic methods.

Original languageEnglish (US)
Pages (from-to)904-907
Number of pages4
JournalBritish Journal of Haematology
Volume189
Issue number5
DOIs
StatePublished - Jun 1 2020
Externally publishedYes

Keywords

  • flow cytometry
  • mass spectrometry
  • multiple myeloma

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma'. Together they form a unique fingerprint.

Cite this